Search By:
Products
Injury
Topic
Company
Industry
Generic drug manufacturers stopped developing competing generic drugs of Adalat and might have conspired to develop only one version, thereby causing all purchasers to pay more than necessary.
Investigation Source
Investigation Scope
Category Information
Investigation Topics
- Over Charge
- Price Fixing
- Overcharging for Drug
Products or Services
- Adalat
- Doctors
- Hospitals
- Healthcare Organizations
- Pharmacists
Injury Type
- Monetary Loss
Investigation Details
Investigation and a pending class action lawsuit against Biovail Corporation, Teva Pharmaceuticals and Elan Corporation on behalf of purchasers of generic Adalat cc 30 mg and 60 mg, generic versions of the blood pressure medicine Adalat CC.
Defendants Biovail Corporation in conjunction with its partner, Teva Pharmaceuticals USA, Inc. and Elan Corporation, plc had been developing rival versions of generic Adalat CC 30 mg and 60 mg.
However, the class action lawsuit alleges that Biovail, Teva and Elan, conspired to ensure that only one version of each drug the 30 mg dosage Adalat and the 60 mg Adalat reached the market. The resulting lack of competition forced purchasers to pay higher prices for the generic drug.
Do not change medications without first consulting your doctor.
Defendants Biovail Corporation in conjunction with its partner, Teva Pharmaceuticals USA, Inc. and Elan Corporation, plc had been developing rival versions of generic Adalat CC 30 mg and 60 mg.
However, the class action lawsuit alleges that Biovail, Teva and Elan, conspired to ensure that only one version of each drug the 30 mg dosage Adalat and the 60 mg Adalat reached the market. The resulting lack of competition forced purchasers to pay higher prices for the generic drug.
Do not change medications without first consulting your doctor.